Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.

its use is restricted within the allergic asthma subtype. The treatment of an already established exacerbation is more straight forward than its prevention. It comprises of oxygenation ...

Emerging research suggests that certain diabetes medications could offer benefits beyond blood sugar control, potentially ...

Treatment for asthma and COPD exacerbations have not changed in 50 years despite causing 3.8 million deaths worldwide a year combined. "Benralizumab is a safe and effective drug already used to ...

Those suffering an “eosinophilic exacerbation” involving eosinophils (a type of white blood cell) were considered suitable for treatment. Around 50% of asthma attacks are eosinophilic ...

Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary disease (COPD), according to a study published online Nov. 27 in The ...

Recent findings from a phase 2 clinical trial reveal that benralizumab, a monoclonal antibody currently used to treat severe asthma, may significantly improve outcomes during asthma and chronic ...

First new treatment for asthma attacks in 50 years hailed as 'game-changer' Doctors and patients have hailed a new treatment for serious asthma and chronic obstructive pulmonary disease (COPD ...

A recent study published in The Journal of Allergy and Clinical Immunology: In Practice found that gestational diabetes ...

Asthma and COPD exacerbations cause nearly four million deaths worldwide each year, but treatment for the chronic conditions has not changed in five decades, she noted. Reuters ...